C U R R IC U L U M V I T A E

Gilbert R. Thompson MD, DSc, FRCP

2C U R R I C U L U M V I T A E

Gilbert Richard THOMPSON

Born: 20th November 1932

Home address : 4A Queen Anne's Gardens,London W4 1TU. Tel/fax: 020-8994-

6143 Email: g.thompson@imperial.ac.uk

Address Metabolic Medicine Division of Investigative Science Imperial College London Hammersmith Hospital, Du Cane Road, London W12 ONN, UK.EDUCATION

Downside School (1946-50)St. Thomas's Hospital, London (1950-56). Kitchener

Scholar

APPOINTMENTS

1956-57 Pre-registration house jobs at St. Mary's Hospital, Portsmouth and Southampton General Hospital

1958-59 Trainee in Medicine, Queen Alexandra Military Hospital, Millbank, London

1959-61 Medical Specialist, Military Hospital, Accra, Ghana

1961-63 Junior Medical Specialist, Queen Alexandra Military Hospital, Millbank, London

1963-65 Registrar in Medicine, Hammersmith Hospital, London

1965-66 Senior Registrar in Medicine, Hammersmith Hospital, London

31966-67 Medical Research Council Travelling Fellowship as Research

Fellow in Medicine at Massachusetts General Hospital, Boston and Harvard Medical School.

1967-72 Lecturer in Medicine, Royal Postgraduate Medical School and Consultant Physician, Hammersmith Hospital, London

July 1972 - Assistant Professor, Division of Atherosclerosis and Lipoprotein Research,

Dec. 1973 Baylor College of Medicine, Houston, Texas (on leave of absence from the Royal Postgraduate Medical School)

1972-74 Senior Lecturer in Medicine, Royal Postgraduate Medical School, London

1975-1983 Consultant, Medical Research Council Lipid Metabolism Unit, Hammersmith Hospital

1983-1993 Consultant, MRC Lipoprotein Team (External Staff), Hammersmith Hospital

1983-1993 Honorary Senior Lecturer in the Department of Medicine, Royal Postgraduate Medical School

1983- 1998 Honorary Consultant Physician in General Medicine, Hammersmith Hospital

1993-1998 Consultant, Lipoprotein Team, MRC Clinical Sciences Centre, Royal Postgraduate Medical School, Hammersmith Hospital

1996-1997 Professor of Clinical Lipidology, Royal Postgraduate Medical School, University of London, Hammersmith Hospital

1997-1998 Professor of Clinical Lipidology, Imperial College School of Medicine, Hammersmith Hospital

1998- Emeritus Professor of Clinical Lipidology, Imperial College School of Medicine, Hammersmith Hospital

2000-2004 Senior Research Investigator, Imperial College School of Medicine, Hammersmith Hospital

DEGREES, DIPLOMAS AND MEMBERSHIPS OF LEARNED SOCIETIES

1956 M.B., B.S. (London)

41959 M.R.C.P. (London); D.T.M. and H.

1963 M.D. (London) Title of Thesis:'Significance of Haemoglobins S and C in Ghana'

1973 F.R.C.P.

2014 DSc. (Imperial College)

5Member Association of Physicians of Great Britain and Ireland

British Atherosclerosis Society (Past Chairman) British Cardiac Society (Extraordinary Member)

British Hyperlipidaemia Association (Past Chairman) European Atherosclerosis Society

RSM Forum on Lipids in Clinical Medicine (Past Chairman)

Distinguished Fellow International Atherosclerosis Society

HONOURS AND AWARDS

1981-82 Lucien Award, McGill University, Montreal, PQ, Canada.Visiting Professor, Cardiovascular Division, Royal

Victoria Hospital, Montreal, Canada.June 1997 Visiting Professor, Division of Endocrinology, Mayo

Clinic, Rochester N.Y., USA.

Cited in ‘Who’s Who in the World’ and Debretts ‘ People of Today’.

COMMITTEES

British Heart Foundation Project Grants Committee (1991-1994)

Simon Broome Heart Research Trust Steering Committee (Past Chairman and Trustee)

Morgagni Prize Committee (University of Padua) (Past Member)

BUPA Foundation Board (Past Member)

EDITORIAL & ADVISORY RESPONSIBILITIES

Advisor, British National Formulary (1987- 2004) Associate Editor, Journal of Lipid Research (1994-1998) Editor, Lipid Review and Lipid Insight (1995-1996) Editor, Current Opinion in Lipidology (First Editor,

1990-1994)

Member of Editorial Board of: Current Opinion in Lipidology

Transplantation Atherosclerosis (Past member)

Cardiovascular Risk Factors (Past member) Journal of Cardiovascular Risk (Past member)

6 Clinical Science (Past member)

BROADCASTS BBC World Service (Science in Action, 1976; Discovery,

1979)BBC Television (Controversy, 1974; Your Life in their

Hands, 1982; Sixty Minutes, 1984; Tomorrows World, 1988)

NEWSPAPER ARTICLES

1. Thompson, G. (l974) Beware sweet reason in the search for causes of heart disease. The Times, July 3l, p. l6.

2. Thompson, G.R. (l990) Dangerous fat. The Times, June 22 (letter).3. Thompson, G.R. (1991) Diet and disease. The Times, March 28th

(letter).

TEACHING ACTIVITIES

Recognised Teacher in Lipid Metabolism in the Faculty of Medicine and Board of Postgraduate Medical Studies, University of London (since 1981)

NON-PROFESSIONAL ACTIVITIES

1994 Top fund-raising runner for British Heart Foundation in London Marathon

7SCIENTIFIC PUBLICATIONS

Books

1. Thompson, G.R. (1989) A handbook of hyperlipidaemia. London: Current Science. Translated into Russian, Turkish and Japanese. Revised edition 1994.

2. Thompson, G.R. and Wilson, P.W. (1992) Coronary risk factors and their assessment. Science Press, London. Revised edition 1997.

3. Illingworth, D.R., Thompson, G.R. and Carlson, L.A. (1996) Clinician’s Manual on Hyperlipidaemia (A.M. Gotto, ed.), 4th edition. Endorsed by the International Atherosclerosis Society and American Heart Association. Science Press, London.

4. Thompson G. (1999) Hammersmith Marathon, RSM Press, London.

5. Thompson, G.R., Dean, J. and Wilson, P.W.F. (2002) Dyslipidaemia in clinical practice. Martin Dunitz, London.

6. Thompson, G.R., Morrell, J. and Wilson, P.W.F. (2006) Dyslipidaemia in clinical practice, 2nd ediition. Informa Healthcare, London.

7. Thompson, G.R. (2008) The Cholesterol Controversy, RSM Press, London

8. Thompson G. (2012) Nobel Prizes that changed Medicine, Imperial College Press, London

9. Thompson G. (2014) Pioneers of Medicine without a Nobel Prize, Imperial College Press, London.

Chapters

1. Thompson, G.R. (l983) Plasma lipids and lipoproteins, and the hyperlipoproteinaemias. In: Biochemical Aspects of Human Disease (ed. R.S. Elkeles), pp. 85-l23. Blackwell, Oxford.

2. Thompson, G.R. (l984) Lipid abnormalities. In: Textbook of Gastroenterology (eds. I.A.D. Bouchier, R.N. Allan, H.J.F. Hodgson and M.R.B. Keighley), pp. 689-693. Baillière Tindall, London.

83. Thompson, G.R. (l984) Cholesterol and the plasma lipoproteins. In:

Clinical Biochemistry of the Elderly (ed. M. Hodkinson), pp. 296-3ll. Churchill Livingstone, London.

4. Thompson, G.R. (l985) The hyperlipidaemias. In: Genetic and Metabolic Disease in Pediatrics (eds. June K. Lloyd and C.R. Scriver), pp. 2ll-233. Butterworths, London.

5. Thompson, G.R. (l987) Non-dietary, non-pharmacological treatment of hyperlipoproteinaemia. In: Atherosclerosis. Biology and clinical science (ed. A.G. Olsson), pp. 43l-436. Churchill Livingstone: Edinburgh.

6. Thompson, G.R. (l989) Hyperlipidaemias. In: Diseases of the Heart (eds D.G. Julian, A.J. Camm, K.M. Fox, R.J.C. Hall, and P.A. Poole-Wilson), pp. l027-l034. Baillière Tindall, London.

7. Galton, D.J. and Thompson, G.R. (eds) (1990) Lipids and Cardiovascular Disease. Br. Med. Bull., vol. 46, Churchill Livingstone: Edinburgh.

8. Thompson, G.R. (l990) Primary hyperlipidaemia. Br. Med. Bull. 46, 986-l004.

9. Thompson, G.R. (1992) Strategies for treating patients with high levels of Lp(a) lipoprotein. In: Genetics of coronary heart disease (ed. A.G. Bearn), pp. 63-74. University of Oslo, Institute of Medical Genetics.

10. Thompson, G.R. (1992) Cholesterol and coronary heart disease. In: The Medical Annual (eds J. Fry & T. Bouchier-Hayes), pp. 125-133. Clinical Press, Bristol.

11. Thompson, G.R. (1993) Lipid abnormalities. In: Gastroenterology. Clinical Science and Practice, 2nd ed. (eds. I.A.D. Bouchier, R.N. Allan, H.J.F. Hodgson and MR.B. Keighley), pp. 1275-1281. W.B. Saunders Co. Ltd., London.

12. Thompson, G.R. (1994) Approaches to treatment of hyperlipidaemia. In: Stabilization of coronary atherosclerosis (ed. D. Waters), pp. 113-125. Science Press, London.

13. Thompson, G.R. and Wilhelmsen, L. (1996) Management of blood lipids. In: Diseases of the Heart: II. Management of Hyperlipidaemias, 2nd ed. (eds. D.G. Julian, A.J. Camm, K.M. Fox, R.J.C. Hall and P.A. Poole-Wilson), pp. 932-943. W.B. Saunders Co. Ltd., London.

914. Thompson, G.R. (1996) Pathophysiology of blood lipids. In: Diseases

of the Heart: II. Management of Hyperlipidaemias, 2nd ed. (eds. D.G. Julian, A.J. Camm, K.M. Fox, R.J.C. Hall & P.A. Poole-Wilson), pp. 77-87. W. B. Saunders Co. Ltd., London.

15. Thompson, G.R. (anonymous) The management of dyslipidaemia. Drugs and Therapeutics Bulletin, 1996.

16. Thompson, G.R. (1997) Treatment of hyperlipidaemia in the absence and presence of symptomatic coronary heart disease. In: Current Issues in Cardiology: Management Strategies (ed. J. McEwan). London: BMJ Publishing Group, pp. 97-118.

17. Thompson, G.R. (1998) To treat or not to treat dyslipidemia in the asymptomatic elderly. In: Vascular disease in the older person (ed. E.G. Lakata). The Novartis Foundation for Gerontological Research series, v. 1. London: The Parthenon Publishing Group Ltd., pp. 105-115.

18. Thompson, G.R. (1999) Familial hypercholesterolaemia. In: Lipoproteins in Health and Disease (eds. D.J. Betteridge, D.R. Illingworth and J. Shepherd). Edward Arnold, pp. 675-692.

19 . Thompson, G.R. (1999). Abnormalities of plasma lipoprotein transport. In: Plasma lipids and their role in disease (ed. P.J. Barter and K-A. Rye). Harwood Academic Publishers, pp.17-43.

20 Thompson, G.R. (2002) Familial Hypercholesterolaemia. In: Oxford Textbook of Endocrinology (ed. J.A.H. Wass and S.M. Shalet), Oxford University Press. pp 1545-1552.

21 Thompson, G.R. (2002) Significance of cholesterol absorption: inhibitory role of plant sterols and stanols. In: Nutrition and Health (T. Carr and K. Descheemaeker, eds), Blackwell Science, Oxford. pp. 27-33.

22 Thompson, G. (2002) Current and future trends in lipid-regulating therapy. In: The Year in Dyslipidaemia 2002 ( P. Durrington, M. Mackness, P. Miller and A. Rees, eds), Clinical Publishing Services, Oxford. pp 335-344.

23 Thompson, G.R. (2002/03) Significance of cholesterol absorption in causation and prevention of coronary heart disease. In: Coronary Care in the UK (E.D.M.Tod, ed), The Association of Primary Care Groups and Trusts, Thornton Heath. pp 45-47.

1024 Brynes, A. and Thompson, G.R. (2003) Functional foods in lipid-

lowering and coronary prevention. In Lipids and Atherosclerosis Annual 2003 (A.Gaw and J.Shepherd, eds), Martin Dunitz, London. Pp 119-138.

25 Thompson, G.R. (2004) Combination therapy with statins. In: Statins: The HMG-CoA Reductase Inhibitors in Perspective. Second edition (A.Gaw, C.Packard and J.Shepherd, eds) Martin Dunitz, London. Pp 189-199.

26. Thompson G. R. (2011) Familial hypercholesterolaemia. In: Oxford Textbook of Endocrinology and diabetes. Second edition ( J.A.H. Wass and P.M. Stewart, eds) Oxford University Press. Pp 1667-73.

27. Thompson G.R. (2012) Lipids, dyslipidaemia and cardiovascular disease. In: Understanding medical research (J.A. Goodfellow, ed) Wiley-Blackwell, Oxford. Pp 46- 57.

28. Thompson G. (2012) The discovery of the LDL receptor and its role in cholesterol metabolism. In: Nobel Prizes that changed Medicine. (G.Thompson, ed) Imperial College Press, London, Pp 217- 235.

29. Scott, J and Thompson G. (2012) The discovery of the structure of DNA. In: Nobel Prizes that changed Medicine. (G.Thompson, ed) Imperial College Press, London, Pp 89- 112.

30. Thompson G and Mabuchi H. (2014) Akira Endo: The Discovery of Statins. In: Pioneers of Medicine without a Nobel Prize. (G.Thompson, ed) Imperial College Press, London, Pp 251- 269.

Original articles, reviews and letters

1. Thompson, G.R. (l960) Westergren versus Wintrobe. J. Roy. Army Med. Corps., l06, ll9-121.

2. Thompson, G.R. and Carter, S.B. (l96l) A controlled trial of Daraclor. W. African Med. J., l0, 93-97.

3. Thompson, G.R. (l962) Further experience with Daraclor. W. African Med. J.. ll, 32-34.

114. Thompson, G.R. (l962) Significance of haemoglobins S and C in

Ghana. Br. Med. J., l, 682-685.

5. Thompson, G.R. and Lehmann, H. (l962) Combination of high levels of haemoglobins A, S and C in Ghana. Br. Med. J., 2, 1521-1523.

6. Thompson, G.R. (l963) Malaria and stress in relation to haemoglobins S and C. Br. Med. J., 2, 976-978.

7. Thompson, G.R., Lewis, B. and Booth, C.C. (l966) Absorption of H3-vitamin D3 in control subjects and patients with intestinal malabsorption. J. Clin. Invest., 45, 94-102.

8. Thompson, G.R., Lewis, B. and Booth, C.C. (l966) Vitamin D absorption of after partial gastrectomy. Lancet, l, 457-458.

9. Thompson, G.R., Neale, G., Watts, J.M. and Booth, C.C. (l966). Detection of vitamin D deficiency after partial gastrectomy. Lancet, l, 623-626.

10. Clinico-Pathological Conference (l967) A case of osteomalacia, osteoporosis and hypercalcaemia. Br. Med. J., l, 2l9-223.

11. Bordier, P., Matrajit, H., Hioco, D., Hepner, G.W., Thompson, G.R. and Booth, C.C. (l968) Subclinical vitamin D deficiency following gastric surgery. Lancet, 2, 437-440.

12. Thompson, G.R., Ockner, R.K. and Isselbacher, K.H. (l969) Effect of mixed micellar lipid on the absorption of cholesterol and vitamin D into lymph. J. Clin. Invest., 48, 87-95.

13. Whittle, H., Blair, A., Neale, G., Thallassinos, N., McLaughlin, M., Marsh, M.N., Peters, T.J., Wedzicha, B. and Thompson, G.R. (l969) Intravenous vitamin D in the detection of vitamin D deficiency. Lancet, l, 747-750.

14. Bordier, P., Hioco, H., Rouquier, M., Hepner, G.W. and Thompson, G.R. (l969) Effects of intravenous vitamin D on bone and phosphate metabolism in osteomalacia. Calc. Tissue Res., 4, 78-83.

15. Middleton, W.R.J. and Thompson, G.R. (l969) The mechanism of steatorrhoea in induced hyperthyroidism in the rat. J. Lab. Clin. Med., 74, l9-30.

16. Thompson, W.G. and Thompson, G.R. (l969) Effect of cholestyramine on the absorption of vitamin D and calcium. Gut, l0, 7l7-722.

1217. Thompson, G.R., McMahon, M. and Claes, P. (l969) Precipitation by

neomycin compounds of fatty acid and cholesterol from mixed micellar solutions. Eur. J. Clin. Invest., l, 40-47.

18. Thompson, G.R. (l970) Vitamin D deficiency after gastrectomy. Sci. Basis Med. Ann. Rev., 260-275.

19. McMahon, M.T. and Thompson, G.R. (l970) Comparison of the absorption of a polar lipid, oleic acid, and a non-polar lipid, alpha-tocopherol from mixed micellar solutions and emulsions. Eur. J. Clin. Invest., l, l6l-166.

20. Thompson, G.R., Barrowman, J., Gutierrez, L. and Dowling, R.H. (l97l) Action of neomycin on the intraluminal phase of lipid absorption. J. Clin. Invest., 50, 3l9-323.

21. McMahon, M.T., Neale, G. and Thompson, G.R. (l97l) Lymphatic and portal venous transport of alpha-tocopherol and cholesterol. Eur. J. Clin. Invest., l, 288-294.

22. Thompson, G.R. and Trexler, P.C. (l97l) Gastrointestinal structure and function in germ-free or gnotobiotic animals. Gut, l2, 230-235.

23. Thompson, G.R., Henry, K., Edington, N. and Trexler, P.C. (l972) Effect of neomycin on cholesterol metabolism in the germ-free pig. Eur. J. Clin. Invest., 2, 365-371.

24. Lewis, B., Thompson, G.R. and Carlson, L. (l972) Hormones and lipid metabolism. Postgrad. Med. J., 48, 6l6-625.

25. Thompson, G.R. and Gotto, A.M. (l973) Ileal bypass in the treatment of hyperlipoproteinaemia. Lancet, 2, 35-36.

26. Shimoyama, T., Kikuchi, H., Press, M. and Thompson, G.R. (l973) Fatty acid composition of plasma lipoproteins in control subjects and patients with malabsorption. Gut, l4, 7l6-722.

27. Thompson, G.R. and Miller, J.P. (l973) Plasma lipid and lipoprotein abnormalities in patients with malabsorption. Clin. Sci., 45, 583-592.

28. Miller, J.P. and Thompson, G.R. (l973) Plasma cholesterol esterification in patients with secondary hypocholesterolaemia. Eur. J. Clin. Invest., 3, 40l-406.

29. Silver, J., Neale, G. and Thompson, G.R. (l974) Effect of phenobarbitone treatment on vitamin D metabolism in mammals. Clin. Sci., 46, 433-448.

1330. Press, M., Kikuchi, H., Shimoyama, T. and Thompson, G.R. (l974)

Diagnosis and treatment of essential fatty acid deficiency in man. Br. Med. J., 2, 247-250.

31. Press, M. and Thompson, G.R. (l974) Plasma post-heparin lipolytic activity in patients with malabsorption: effect of intravenous fat administration. Clin. Sci., 46, 743-751.

32. Thompson, G.R., Heath, J. and Press, M. (l974) Changes in the fatty acid composition of plasma lipoproteins during administration of intralipid to a patient with essential fatty acid deficiency. Clin. Sci., 47, 387-392.

33. Thompson, G.R., Segura, R., Hoff, H. and Gotto, A.M. (l975) Contrasting effects on plasma lipoproteins of intravenous versus oral administration of a triglyceride-phospholipid emulsion. Eur. J. Clin. Invest., 5, 373-384.

34. Thompson, G.R., Lowenthal, R. and Myant, N.B. (l975) Plasma exchange in the management of homozygous familial hypercholesterolaemia. Lancet, l, l208-1211.

35. David, J.S.K., Thompson, G.R., Gotto, A.M. and Morrisett, J.D. (l975) Interaction of human plasma apolipoproteins and phospholipids. Semi-quantitative studies using polyacrylamide gel electrophoresis. Biochim. Biophys. Acta, 398, 72-83.

36. Thompson, G.R. and Myant, N.B. (l976) Low density lipoprotein turnover in familial hypercholesterolaemia after plasma exchange. Atherosclerosis, 23, 37l-377.

37. Thompson, G.R., Birnbaumer, M.E., Levy, R.I. and Gotto, A.M. (l976) Solid phase radio immunoassay of apolipoprotein B (apo-B) in normal human plasma. Atherosclerosis, 24, l07-118.

38. Thompson, G.R., Jadhav, A., Nava, M. and Gotto, A.M. (l976) Effects of intravenous phospholipid on low density turnover in man. Eur. J. Clin. Invest., 6, 24l-248.

39. Myant, N.B., Reichl, D., Thompson, G.R., Higgins, M.J.P. and Galton, D.J. (l976) The metabolism in vivo and in vitro of low density lipoprotein from a subject with inherited hypercholesterolaemia. Clin. Sci. Mol. Med., 5l, 463-465.

40. Thompson, G.R. (l976) HDL and CHD. Lancet, 2, l3l-132. [unsigned editorial].

1441. Marsh, A.R., Fraser, H.S., Breckenridge, A., Lewis, B. and Thompson,

G.R. (l977) Accentuation of ethanol-induced fatty liver by phenobarbitone. Clin. Sci. Mol. Med., 52, 2l9-222.

42. Thompson, G.R., Spinks, T., Ranicar, A. and Myant, N.B. (l977) Non-steady-state studies of low density lipoprotein turnover in familial hypercholesterolaemia. Clin. Sci. Mol. Med., 52, 36l-369.

43. Thompson, G.R. (l977) Serum cholesterol and the soya bean. Lancet, l, 29l-292. [unsigned editorial].

44. Thompson, G.R. (l977) Of mice, men and trypanosomes. Lancet, 2, 860-861 [unsigned editorial].

45. Soutar, A.K., Myant, N.B. and Thompson, G.R. (l977) Simultaneous measurement of apolipoprotein B turnover in very low and low density lipoproteins in familial hypercholesterolaemia. Atherosclerosis, 28, 247-256.

46. Thompson, G. (l978) Plasma lipoproteins and their disorders. Medicine, 3rd series, ll, 558-564.

47. Thompson, G.R. (l979) Management of familial hypercholesterol-aemia and new approaches to the treatment of atherosclerosis. In: Atherosclerosis Reviews, Vol. 5 (eds. R. Paoletti and A.M. Gotto Jr.), pp. 67-90. Raven Press, New York.

48. Kilpatrick, D., Fleming, J., Clyne, C. and Thompson, G.R. (l979) Reduction of blood viscosity following plasma exchange. Atherosclerosis, 32, 30l-306.

49. Jadhav, A. and Thompson, G.R. (l979) Reversible abnormalities of low density lipoprotein composition in familial hypercholesterol-aemia. Eur. J. Clin. Invest., 9, 63-67.

50. Soutar, A.K., Myant, N.B. and Thompson, G.R. (l979) Metabolism of apolipoprotein-B-containing lipoproteins in familial hyper-cholesterolaemia. Effects of plasma exchange. Atherosclerosis, 32, 3l5-325.

51. Partridge, M.R., Hughes, J.M.B. and Thompson, G.R. (l979) Effect of hyperlipidaemia on pulmonary diffusing capacity for carbon monoxide. Thorax, 34, 265-268.

52. Thompson, G.R. and Myant, N.B. (l980) Regression of atherosclerosis (letter). Atherosclerosis, 35, 347-348.

1553. Thanabalasingham, S., Thompson, G.R., Trayner, I., Myant, N.B. and

Soutar, A.K. (l980) Effect of lipoprotein concentration and lecithin:cholesterol acyltransferase activity on cholesterol esterification in human plasma after plasma exchange. Eur. J. Clin. Invest., l0, 45-48 .

54. Lowenthal, R.M., Marsden, K.A., Dewar, C.L. and Thompson, G.R. (l980) Congenital dyserythropoietic anaemia (CDA) with severe gout, rare cell phenotype and erythrocyte, granulocyte and platelet membrane re-duplication: a new variant of CDA type II. Br. J. Haematol., 44, 2ll-220.

55. Trayner, I.M., Mannarino, E., Clyne, C.A.C. and Thompson, G.R. (l980) Serum lipids and high density lipoprotein cholesterol in peripheral vascular disease. Br. J. Surg., 67, 497-499.

56. Thompson, G.R., Myant, N.B., Kilpatrick, D., Oakley, C.M., Raphael, M.J. and Steiner, R.E. (l980) Assessment of long-term plasma exchange for familial hypercholesterolaemia. Br. Heart J., 43, 680-688.

57. Allen, J.M., Thompson, G.R., Myant, N.B., Steiner, R. and Oakley, C.M. (l980). Cardiovascular complications of homozygous familial hypercholesterolaemia. Br. Heart J., 44, 36l-368.

58. Thompson, G.R., Trayner, I., Danford, W., Mark, F. and Harrison, R. (l980) Plasma lipids and lipoproteins after modified fat diet. Lancet, 2, 42l [letter].

59. Kaufman, S., Kaufman, B., Reynolds, D., Trayner, I. and Thompson, G.R. (l980) Effects of jogging on serum low density lipoprotein cholesterol. Artery, 7, 99-l08.

60. Thompson, G.R., Soutar, A.K., Spengel, F.A., Jadhav, A., Gavigan, S.J.P. and Myant, N.B. (l98l) Defects of receptor-mediated low density lipoprotein catabolism in homozygous familial hyper-cholesterolemia and hypothyroidism in vivo. Proc. Natl. Acad. Sci. USA, 78, 259l-2595.

61. Thompson, G.R. (l98l) Dietary and pharmacological control of lipoprotein metabolism. In: Lipids, Lipoproteins and Atherosclerosis (ed. N.E. Miller and B. Lewis), pp. l29-l43. Elsevier/North Holland Biomedical Press, Amsterdam.

62. Thompson, G.R. (l98l) Plasma exchange for hypercholesterolaemia. Lancet, l, l246-l248.

1663. Spengel, F.A., Jadhav, A., Duffield, R.G.M., Wood, C.B. and Thompson,

G.R. (l98l) Superiority of partial ileal bypass over cholestyramine in reducing cholesterol in familial hypercholesterolaemia. Lancet, l, 768-770.

64. Sugrue, D.D., Thompson, G.R., Oakley, C.M., Trayner, I.M. and Steiner, R.E. (l98l) Contrasting patterns of coronary atherosclerosis in normocholesterolaemic smokers and patients with familial hypercholesterolaemia. Br. Med. J., 283, l358-l360.

65. Spengel, F.A. and Thompson, G.R. (l98l) Receptor-mediated low density lipoprotein catabolism. Klin. Wochenschr., 60, 3l9-325.

66. Soutar, A.K., Myant, N.B. and Thompson, G.R. (l98l) The metabolism of very-low-density and intermediate-density lipoproteins in patients with familial hypecholesterolaemia. Atherosclerosis, 43, 2l7-23l.

67. Borysiewicz, L.K., Soutar, A.K., Evans, D.J., Thompson, G.R. and Rees, A.J. (l982) Renal failure in familial lecithin:cholesterol acyl-transferase deficiency. Q. J. Med., 5l, 4ll-426.

68. Spengel, F.A., Harders-Spengel, K., Duffield, R., Wood, C., Myant, N.B. and Thompson, G.R. (l982) The effect of partial ileal bypass on receptor-mediated uptake and catabolism of low density lipoprotein in the Rhesus monkey. Res. Exp. Med. (Berlin), l80, 263-270.

69. Harders-Spengel, K., Wood, C.B., Thompson, G.R., Myant, N.B. and Soutar, A.K. (l982) Difference in saturable binding of low density lipoprotein to liver membranes from normocholesterolemic subjects and patients with heterozygous familial hypercholesterolemia. Proc. Natl. Acad. Sci. USA, 79, 6355-5359.

70. Thompson, G. and Soutar, A. (l983) Genetic polymorphism and plasma lipoproteins. Nature, 30l, 658.

71. Ribiero, P., Jadhav, A.V., Walesby, R., Trayner, I., Edmondson, S., Oakley, C.M. and Thompson, G.R. (l983) Collagen content of atherosclerotic arteries is higher in smokers than in non-smokers. Lancet, l, l070-l073.

72. Allen, J.M., Thompson, G.R. and Myant, N.B. (l983) Normal adrenocortical response to adrenocorticotrophic hormone in patients with homozygous familial hypercholesterolaemia. Clin. Sci., 65, 99-l0l.

1773. von Arnim, T., Crea, F., Chierchia, S., Thompson, G.R. and Maseri, A.

(l983) Effects of vasoactive stimuli on coronary vascular resistance in isolated perfused rabbit hearts: no vasospastic response to ergonovine with or without atherogenic diet. Basic Res. Cardiol., 78, 4l5-422.

74. Ribiero, P., Shapiro, L.M., Gonzalez, A., Thompson, G.R. and Oakley, C.M. (l983) Cross sectional echocardiographic assessment of the aortic root and coronary ostial stenosis in familial hypercholesterolaemia. Br. Heart J., 50, 432-437.

75. Teng, B., Thompson, G.R., Sniderman, A.D., Forte, T.M., Krauss, R.M. and Kwiterovich, P.O. (l983) Composition and distribution of low density lipoprotein fractions in hyperapobetalipoproteinemia, normolipidemia and familial hypercholesterolemia. Proc. Natl Acad. Sci. USA, 80, 6662-6666.

76. Allen, J.M., Sarson, D.L., Adrian, T.E., Wood, C., Thompson, G.R. and Bloom, S.R. (l983) Effect of partial ileal bypass on the gut hormone responses to food in man. Digestion, 28, l9l-l96.

77. Murphy, M.B., Sugrue, D., Trayner, I., Kaufman, S., Yasuhara, H., Dollery, C.T. and Thompson, G.R. (l984) Effects of short term beta-adrenoreceptor blockade on serum lipids and lipoproteins in patients with hypertension or coronary artery disease. Br. Heart J., 5l, 589-594.

78. Thompson, G.R. (l984) Apoproteins - determinants of lipoprotein metabolism and indices of coronary risk. Br. Heart J., 5l5, 585-588.

79. Rowe, I.F., Soutar, A.K., Trayner, I.M., Thompson, G.R. and Pepys, M.B. (l984) Circulating human C-reactive protein binds very low density lipoproteins. Clin. exp. Immunol., 58, 237-244.

80. Angel, A., Thanabalasingham, S., Reichl, D., Pflug, J.J., Thompson, G.R. and Myant, N.B. (l984) Effects of starvation and plasma exchange on lecithin: cholesterol acyltransferase activity and cholesterol efflux in cholesterol-fed pigs. Res. Exp. Med., l84, 23l-242.

81. ffrench-Constant, C.K., Spengel, F.A. and Thompson, G.R. (l985) Hyperlipidaemia and premature coronary artery disease associated with sex-change in a female. Postgrad. Med. J., 6l, 6l-63.

82. Sugrue, D.D., Trayner, I., Thompson, G.R., Vere, V.J., Imeson, J.D., Stirling, Y. and Meade, T.W. (l985) Coronary artery disease and haemostatic variables in heterozygous familial hypercholesterol-aemia. Br. Heart J., 53, 265-268.

18

83. Thompson, G. and Sapsford, R. (l985) Coronary artery bypass grafting and hyperlipidaemia. Br. Heart J., 53, 237-239.

84. Crea, F., von Arnim, T., Allwork, S.P., Jadhav, A., Thompson, G.R. and Maseri, A. (l985) Failure of experimental atherosclerosis to sensitive coronary arteries to spasm in hypercholesterolemic rabbits. Am. Heart J., l09, 49l-497.

85. Thompson, G.R., Miller, J.P. and Breslow, J.L. (l985) Improved survival of patients with homozygous familial hypercholesterolaemia treated by plasma exchange. Br. Med. J., 29l, l67l-l673.

86. Sanders, T.A.B., Sullivan, D.R., Reeve, J. and Thompson, G.R. (l985) Triglyceride-lowering effect of marine polyunsaturates in patients with hypertriglyceridaemia. Arteriosclerosis, 5, 459-465.

87. Knight, B.L., Thompson, G.R. and Soutar, A.K. (l986) Binding and degradation of heavy and light subfractions of low density lipoprotein by cultured fibroblasts and macrophages. Atherosclerosis, 59, 30l-306.

88. Teng, B., Sniderman, A.D., Soutar, A.K. and Thompson, G.R. (l986) Metabolic basis of hyperapobetalipoproteinemia. Turnover of apolipoprotein B in low density lipoprotein and its precursors and subfractions compared with normal and familial hypercholesterolemia. J. Clin. Invest., 77, 663-672.

89. Sullivan, D.R., Sanders, T.A.B., Trayner, I.A.M., and Thompson, G.R. (l986) Paradoxical elevation of LDL apoprotein B levels in hyper-triglyceridaemic patients and normal subjects ingesting fish oil. Atherosclerosis, 6l, l29-l34.

90. Thompson, G.R., Ford, Judith, Jenkinson, M. and Trayner, Iris (l986) Efficacy of mevinolin as adjuvant therapy for refractory familial hypercholesterolaemia. Q. J. Med., 60, 803-8ll.

91. Thompson, G.R. (l986) Lipids, fish and coronary heart disease. Curr. Opin. Cardiol., l, 827-83l.

92. Thompson, G.R. (l986) New hopes for the treatment of coronary heart disease. Nature, 324, 4l2.

93. Thompson, G.R. (l987) Evidence that lowering serum lipids favourably influences coronary heart disease. Q. J. Med., New Series 62, 87-95.

1994. Thompson, G.R., Teng, B. and Sniderman, A. (l987) Kinetics of LDL

sub-fractions. Am. Heart J., ll3, 5l4-5l7.

95. Kano, M., Koizumi, J., Jadhav, A. and Thompson, G.R. (l987) Plasma exchange and low density lipoprotein apheresis in Watanabe Heritable Hyperlipidemic rabbits. Arteriosclerosis, 7, 256-26l.

96. Shepherd, J., Betteridge, D.J., Durrington, P., Laker, M., Lewis, B., Mann, J., Miller, J.P., Reckless, J.P.D. and Thompson, G.R. (l987) Strategies for reducing coronary heart disease and desirable limits for blood lipid concentrations: guidelines of the British Hyperlipidaemia Association. Br. Med. J., 295, l245-l246.

97. Thompson, G.R. (l987) Cardiac catheterization in homozygous familial hypercholesterolaemia. Atherosclerosis, 66, l73 (letter).

98. Thompson, G.R. (l988) Lipid-lowering drugs. Lancet, 1, 597 (letter).

99. Allaway, S.L., Ritchie, C.D., Robinson, D., Seear, T., Reznek, R., Kelsey Fry, I. and Thompson, G.R. (l988) Detection of alcohol-induced fatty liver by computerized tomography. J. Roy. Soc. Med., 8l, l49-l5l.

100. Barbir, M., Wile, D., Trayner, I., Aber, V.R. and Thompson, G.R. (l988) High prevalence of hypertriglyceridaemia and apolipoprotein abnormalities in coronary artery disease. Br. Heart J., 60, 397-403.

101. Koizumi, J., Kano, M., Okabayashi, K., Jadhav, A. and Thompson, G.R. (l988) Behavior of human apolipoprotein A-I:phospholipid and apoHDL:phospholipid complexes in vitro and after injection into rabbits. J. Lipid Res., 29, l405-l4l5.

102. Barbir, M., Michishita, I., Larkin, S. and Thompson, G.R. (l989) Computer analysed angiogram of a plaque in the circumflex artery of an hypercholeterolaemic patient before and after l8 months' treatment. Br. Med, J., 298, l32.

103. Thompson, G.R. (l989) Current management of hyperlipidaemia. Br. J. Hosp. Med., 42, 268-274.

104. Thompson, G.R. (l989) Management of hyperlipidaemia. Prescribers' Journal, 29, 221-233.

105. Thompson, G.R. (l989) Saturation of fat and cholecystokinin release. Lancet, 2, 1338 (letter).

106. Thompson, G.R., Barbir, M., Okabayashi, K., Trayner, I. and Larkin, S. (l989) Plasmapheresis in familial hypercholesterolemia. Arteriosclerosis, Supplement I, 9, I-l52-I-l57.

20

107. Thompson, G.R., Seed, M., Niththyananthan, S., McCarthy, S. and Thorogood, M. (l989) Genotypic and phenotypic variation in familial hypercholesterolemia. Arteriosclerosis, Supplement I, 9, I-75-I-80.

108. Davis, T.M.E., Proby, C., Strong, J.A., Thompson, G.R., Massey, H., Scott, R. and Bloom, S.R. (l989) Effect of enprostil on glucose and lipid metabolism in type 2 diabetes. Diab. Med., 6, 400-405.

109. Maher, V.M.G., Pappu, A., Illingworth, D.R. and Thompson, G.R. (l989) Plasma mevalonate response in lovastatin-related myopathy. Lancet, 2, l098 (letter).

110. Myant, N.B., Gallagher, J., Barbir, M., Thompson, G.R., Wile, D. and Humphries, S.E. (l989) Restriction fragment length polymorphisms in the apoB gene in relation to coronary artery disease. Atherosclerosis, 77, l93-20l.

111. Ohri, S.K., Keane, P.F., Swift, I., Sackier, J.M., Williamson, R.C.N., Thompson, G.R. and Wood, C.B. (l989) Reappraisal of partial ileal bypass for the treatment of familial hypercholesterolemia. Am. J. Gastroenterol., 84, 740-743.

112. Utermann, G., Hoppichler, F., Dieplinger, H., Seed, M., Thompson, G.R. and Boerwinkle, E. (l989) Defects in the low density lipoprotein receptor gene affect lipoprotein (a) levels: Multiplicative interaction of two gene loci associated with premature atherosclerosis. Proc. Natl Acad. Sci. USA, 86, 4l7l-4l74.

113. Wile, D.B., Barbir, M., Gallagher, J., Myant, N.B., Ritchie, C.D., Thompson, G.R. and Humphries, S.E. (l989) Apolipoprotein A-I gene polymorphisms: frequency in patients with coronary artery disease and healthy controls and association with serum apoA-I and HDL-cholesterol concentration. Atherosclerosis, 78, 9-l8.

114. Thompson, G.R. (l990) Hyperlipidemia and the progression of disease in the coronary circulation. Curr. Opin. Cardiol. 5, 753-757.

115. Maher, V.M.G. and Thompson, G.R. (l990) HMG CoA reductase inhibitors as lipid-lowering agents: five years experience with lovastatin and an appraisal of simvastatin and pravastatin. Q.J. Med., 74, l65-l75.

116. Seed, M., Hoppichler, F., Reaveley, D., McCarthy, S., Thompson, G.R., Boerwinkle, E. and Utermann, G. (l990) Relation of serum lipoprotein(a) concentration and apolipoprotein(a) phenotype to coronary heart disease in patients with familial hypercholesterolemia. N. Engl. J. Med., 322, l494-l499.

21

117. Thompson, G.R. (l99l) What should be done about asymptomatic hypercholesterolaemia? Br. Med. J., 302, 605-606.

118. Thompson, G.R. (1991) Guidelines on management of hyperlipidaemia. Br. Med. J., 302, 239 (letter).

119. Thompson, G.R. (1991) Cholesterol lowering and non-cardiac mortality. Lancet, 338, 126 (letter).

120. Thompson, G.R. (1991) Dietary reduction of serum cholesterol concentration. Br. Med. J., 303, 1332 (letter).

121. Barbir, M., Banner, N., Thompson, G.R., Khaghani, A., Mitchell, A. & Yacoub, M. (1991) Relationship of immunosuppression and serum lipids to the development of coronary arterial disease in the transplanted heart. Internat. J. Cardiol., 32, 51-56.

122. Laker, M., Reckless, J., Betteridge, J., Durrington, P., Miller, P., Nicholls, P., Shepherd, J. & Thompson, G. (1991) Facilities for the management of patients with lipid disorders in the United Kingdom: results of the British Hyperlipidaemia Association Survey. Health Trends, 23, 147-149

123. Maher, V.M.G., Gallagher, J.J., Thompson, G.R. and Myant, N.B. (1991) Response to cholesterol-lowering drugs in familial defective apolipoprotein B-100. Atherosclerosis., 91, 73-76.

124. Michishita, I. and Thompson, G.R. (1991) Cholesterol flux in cholesterol ester-loaded macrophages in an in vitro perfusion system. Atherosclerosis, 88, 203-211.

125. Scoppola, A., Maher, V.M.G., Thompson, G.R., Rendell, N.B. and Taylor, G.W. (1991) Quantitation of plasma mevalonic acid using gas chromatography-electron capture mass spectrometry. J. Lipid Res., 32, 1057-1060.

126. Scientific Steering Commitee on behalf of the Simon Broome Register Group (1991) Risk of fatal coronary heart disease in familial hypercholesterolaemia. Br. Med. J., 303, 893-896.

127. Laker, M.F., Reckless, J.P.D., Betteridge, D.J., Durrington, P.N., Miller, J.P., Nicholls, D.P., Shepherd, J. and Thompson, G.R. (1992) Laboratory facilities for investigating lipid disorders in the United Kingdom: Results of the British Hyperlipidaemia Association Survey. J. Clin. Pathol., 45, 102-105.

22128. Maher, V.M.G., Gallagher, J.J., Thompson, G.R. and Myant, N.B.

(1992) Cholesterol-lowering drugs in familial defective apolipoprotein B-100. Lancet, 339, 811.

129. Maher, V.M.G., Trainer, P.J., Scoppola, A., Anderson, J.V., Thompson, G.R. and Besser, G.M. (1992) Possible mechanism and treatment of o,p’DDD-induced hypercholesterolaemia. Q. J. Med., 84, 671-679.

130. Maher V.M.G., Kitano, Y., Neuwirth C., Gallagher, J.J., Thompson, G.R. & Myant, N.B. (1992) Effective reduction of plasma LDL levels by LDL apheresis in familial defective apolipoprotein B-100. Atherosclerosis, 95, 231-234.

131. Thompson, G.R. (1992) Frequency of citation and outcome of cholesterol lowering trials. Br. Med. J., 305, 422 (letter)

132. Thompson, G.R. (1992) Statins and the central nervous system. In: What every doctor wants to know about cholesterol: answers to some difficult questions (ed. P.N. Durrington). Postgrad. Med. J., 68, 871-872.

133. Oliver, M.F. for MAAS Steering Committee (1992) Coronary atheroma regression trials. Lancet, 339, 1241 (letter).

134. Sun, X-M., Webb, J.C., Gudnason, V., Humphries, S., Seed, M., Thompson, G.R., Knight, B.L. and Soutar A.K. (1992) Characterization of deletions in the LDL receptor gene in patients with familial hypercholesterolaemia in the United Kingdom. Arterioscler. Thromb., 12, 762-770.

135. Thompson, G.R. (1992) Progression and regression of coronary artery disease. Curr. Opin. Lipidol. 3, 263-267.

136. Barbir, M., Kushwaha, S., Hunt, B., Macken, A., Thompson, G.R., Mitchell, A., Robinson, D. and Yacoub, M. (1992). Lipoprotein(a) and accelerated coronary artery disease in cardiac transplant recipients. Lancet, 340, 1500-1502.

137. Barbir, M., Khaghani, A., Kehely, A., Tan, K-C., Mitchell, A., Thompson, G.R. and Yacoub, M. (1992) Normal levels of lipoproteins including lipoprotein(a) after liver-heart transplantation in a patient with homozygous familial hyper-cholesterolaemia. Q. J. Med., 85, 807-812.

138. Barbir, M., Hunt, B., Kushwaha, S., Kehely, A., Prescot, R., Thompson, G.R., Mitchell, A. and Yacoub, M. (1992) Maxepa versus bezafibrate in hyperlipidemic cardiac transplant recipients. Am. J. Cardiol., 70, 1596-1601.

23

139. Thompson, G.R. (1993) HMG CoA reductase inhibitors and diet in familial hypercholesterolaemia. Q. J. Med. 86, 70 (letter).

140. Thompson, G.R. (1993) Treatment of hyperlipidaemia. Clin. Endocrin., 38, 337-342.

141. Thompson, G.R. (1993) Simvastatin and pravastatin. Prescribers' Journal, 33, 217-220.

142. Betteridge, D.J., Dodson, P.M., Durrington, P.N., Hughes, E.A., Laker, M.F., Nicholls, D.P., Rees, J.A.E., Seymour, C.A., Thompson, G.R., Winder, A.F., Winocour, P.H. and Wray, R. (1993) Management of hyperlipidaemia: guidelines of the British Hyperlipidaemia Association. Postgrad. Med. J. 69, 359-369.

143. Dumont, J-M. on behalf of the MAAS Research Group. (1993) Effect of cholesterol reduction by simvastatin on progression of coronary atherosclerosis. Design, baseline characteristics, and progress of the multicenter anti-atheroma study (MAAS). Controlled Clin. Trials 14, 209-228.

144. Kitano, Y. and Thompson, G.R. (1993) Role of LDL apheresis in the management of hypercholesterolaemia. Transfus. Science, 14, 269-280.

145. Thompson, G.R., Naoumova, R., Sidhu, P. and Underwood, R. (1994) Predicting coronary heart disease. Lancet, 343, 670-671 (letter).

146. Illingworth, D.R., Erkelens, D.W., Keller, U., Thompson, G.R. & Tikkanen, M.J. (1994) Defined daily doses in relation to hypolipidaemic efficacy of lovastatin, pravastatin, and simvastatin. Lancet, 343, 1554-1556.

147. MAAS Investigators (1994) Effect of simvastatin on coronary atheroma: the Multicentre Anti-Atheroma Study (MAAS). Lancet, 344, 633-638.

148. Russell-Jones, D.L., Watts, G.F., Weissberger, A., Naoumova, R., Myers, J., Thompson, G.R. and Sönksen, P.H. (1994) The effect of growth hormone replacement on serum lipids, lipoproteins, apolipoproteins and cholesterol precursors in adult growth hormone deficient patients. Clin. Endocrinol., 41, 345-350.

149. Naoumova, R.P., Keogh, B., Taylor, K. and Thompson, G.R. (1994) A cautionary tale of undetected hyperlipidaemia: implications for coronary artery bypass grafting. Br. Heart J., 72, 468-469.

24150. Pfohl, M., Naoumova, R.P., Klass, C., Knisel W., Jakober, B., Risler, T.

and Thompson, G.R. (1994) Acute and chronic effects on cholesterol biosynthesis of LDL-apheresis with or without concomitant HMG-CoA reductase inhibitor therapy. J. Lipid Res., 35, 1946-1955.

151. Thompson, G.R., Maher, V.M.G., Matthews, S., Kitano, Y., Neuwirth, C., Shortt, M.B., Davies, G., Rees, A., Mir, A., Prescott, R.J., de Feyter, P. and Henderson, A. (1995) Familial hypercholesterolaemia regression study: a randomised trial of low-density-lipoprotein apheresis. Lancet, 345, 811-816.

152. Thompson, G.R. on behalf of the FHRS Investigators (1995) Low-density-lipoprotein apheresis. Lancet, 346, 117 (letter).

153. Kehely, A., MacMahon, M., Barbir, M., Wray, R., Hunt, B.J., Prescott, R.J. and Thompson, G.R. (1995) Combined bezafibrate and simvastatin treatment for mixed hyperlipidaemia. Q. J. Med., 88, 421-427.

154. Cummings, M.H., Watts, G.F., Umpleby, A.M., Hennessy, T.R., Naoumova, R., Slavin, B.M., Thompson, G.R. and Sönksen, P.H. (1995) Increased hepatic secretion of very-low-density lipoprotein apolipoprotein B-100 in NIDDM. Diabetologia 38, 959-967.

155. Cummings, M.H., Watts, G.F., Pal, C., Umpleby, M., Hennessy, T.R., Naoumova, R. And Sönksen, P.H. (1995) Increased hepatic secretion of very-low-density-lipoprotein apolipoprotein B-100 in obesity: a stable isotope study. Clin. Sci., 88: 225-233.

156. Watts, G.F., Naoumova, R., Cummings, M.H., Umpleby, A.M., Slavin, B.M., Sönksen, P.H. and Thompson G.R. (1995) Direct correlation between cholesterol synthesis and hepatic secretion of apolipoprotein B-100 in normlipidaemic subjects. Metabolism 44, 1052-1057.

157. Watts, G.F., Cummings, M.H., Umpleby, M., Quiney, J.R., Naoumova, R., Thompson, G.R. and Sönksen, P.H. (1995) Simvastatin decreases the hepatic secretion of very-low-density lipoprotein apolipoprotein B-100 in heterozygous familial hypercholesterolaemia: pathophysiological and therapeutic implications. Eur. J. Clin. Invest., 25, 559-567.

158. Thompson, G.R. (1995) Angiographic trials of lipid-lowering therapy: end of an era? Br. Heart J., 74, 343-347.

25159. Maher, V.M.G., Gallagher, J.J., Thompson, G.R. and Myant, N.B.

(1995) Does the presence of the 3500 mutant apolipoprotein B-100 in low density lipoprotein particles affect their atherogenicity? Atherosclerosis, 118: 105-110.

160. Narang, R., Niththyananthan, S., Nonis, C., Thompson, G.R. and Davies, G.J. (1995) Lipoprotein(a) may have contrasting effects on different aspects of atherosclerotic coronary disease. Circulation, 92: 2354-2355.

161. Thompson, G.R., Hollyer, J. and Waters, D.D. (1995) Percentage change rather than plasma level of LDL-cholesterol determines therapeutic response in coronary heart disease. Curr. Opin. Lipidol., 6: 386-388.

162. Naoumova, R.P., Marais, A.D., Mountney, J., Firth, J.C., Rendell, N. B., Taylor, G.W. and Thompson, G.R. (1996) Plasma mevalonic acid, an index of cholesterol synthesis in vivo, and responsiveness to HMG-CoA reductase inhibitors in familial hypercholesterolaemia. Atherosclerosis, 119: 203-213.

163. Naoumova, R.P., Cummings, M.H., Watts, G.F., Rendell, N.B., Taylor, G.W., Sönksen, P.H. and Thompson, G.R. (1996) Acute hyperinsulinaemia decreases cholesterol synthesis less in NIDDM than in non-diabetic subjects. Eur. J. Clin. Invest., 26: 332-340.

164. Sidhu P., Naoumova, R.P., Maher, V.M.G., MacSweeney J.E., Neuwirth C.K.Y., Hollyer, J.S. and Thompson, G.R. (1996) The extracranial carotid artery in familial hypercholesterolaemia. The relationship of intima-media thickness and plaque morphology with plasma lipids and coronary heart disease. J. Cardiovasc. Risk, 3: 61-67.

165. Maher, V.M.G. and Thompson, G.R. (1996) LDL apheresis: role in the treatment of atherosclerosis. J. Irish Coll. Physicians & Surgeons, 25: 96-99.

166. Thompson, G.R. (1996) Lipid lowering in the young. Heart, 76: 1-2.

167. Webb, J.C., Sun, X-M., McCarthy, S.M., Neuwirth, C., Thompson, G.R., Knight, B.L. and Soutar, A.K. (1996) Characterisation of mutations in the low density lipoprotein (LDL)-receptor gene in patients with homozygous familial hypercholesterolaemia and determination of the frequency of these mutations in FH patients in the UK. J. Lipid Res., 37: 368-381.

168. Thompson, G.R., Naoumova, R. and Watts, G.F. (1996) Role of cholesterol in regulating apolipoprotein B secretion by the liver. J. Lipid Res., 37: 439-447..

26

169. Rallidis, L., Nihoyannopoulos, P. and Thompson, G.R. (1996) Aortic stenosis in homozygous familial hypercholesterolaemia. Heart, 76: 84-85.

170. Hoffer, M.J.V., Niththyananthan, S., Naoumova, R.P., Kibirige, M.S., Frants, R.R., Havekes, L.M. and Thompson, G.R. (1996) Apolipoprotein E1-Hammersmith (Lys 147 Asn; Arg 147 Trp), due to a dinucleotide substitution, is associated with early manifestation of dominant type III hyperlipoproteinaemia. Atherosclerosis, 124: 183-189.

171. Thompson, G.R., Forbat, S. and Underwood, R. (1996) Electron beam (ultrafast) CT scanning for coronary calcification: potential for predicting coronary heart disease. Q. J. Med., 89: 565-570.

172. Thompson, G.R. (1996) Statins and coronary heart disease. Lancet, 348: 57

173. Haider, A.W., Andreotti, F., Thompson, G.R., Kluft, C., Maseri, A. and Davies, G.J. (1996) Serum lipoprotein(a) level is related to thrombin generation and spontaneous intermittent coronary occlusion in patients with acute myocardial infarction. Circulation, 94: 2072-2076.

174. Thompson, G.R. (1997) What targets should lipid-modulating therapy achieve to optimise the prevention of coronary heart disease. Atherosclerosis 131: 1-5.

175. Naoumova, R.P., Dunn, S., Rallidis, L., Abu-Muhana, O., Neuwirth, C., Rendell, C., Rendell, N.B., Taylor, G.W. and Thompson, G.R. (1997) Prolonged inhibition of cholesterol synthesis explains the efficacy of atorvastatin. J. Lipid Res. 38: 1496-1500.

176. Marais, A.D., Naoumova, R.P., Firth, J.C., Penny, C., Neuwirth, C.K.Y. and Thompson, G.R. (1997) Decreased production of low density lipoprotein production by atorvastatin after apheresis in homozygous familial hypercholesterolaemia. J Lipid Res. 38: 2071-2078.

177. Pfohl, M., Naoumova, R.P., Neuwirth, C., Sussekov, A., Smykowski, J., Rendell, N.B., Taylor, C.W., Seif, F.J. and Thompson, G.R. (1997) Upregulation of cholesterol synthesis after acute reduction of low density lipoprotein by apheresis in normocholesterolaemic subjects: evidence for a threshold effect. Atherosclerosis, 135: 257-262.

27178. Riches, F.M., Watts, G.F., Naoumova, R.P., Kelly, J.M., Croft, K.D. and

Thompson, G.R. (1997) Direct association between the hepatic secretion of very-low density apolipoprotein B100 plasma mevalonic acid and lathosterol concentrations in normolipidaemic subjects. Atherosclerosis, 135: 83-91.

179. Watts, G.F., Naoumova, R.P., Kelly, J.M., Riches, F.M., Croft, K.D. and Thompson, G.R. (1997) Inhibition of cholesterogenesis decreases hepatic secretion of apolipoprotein B-100 in normolipidaemic subjects. Am. J. Physiol., 273 (Endocrinol. Metab. 36): E462-E470.

180. Betteridge, J., Shepherd, J. and Thompson, G.R. (1997) Sheffield tables have shortcomings. Br. Med. J., 315: 1619.

181. Thompson, G.R. and Naoumova, R.P. (1998) New prospects for lipid-lowering drugs. Exp. Opin. Invest. Drugs, 7: 715-727.

182. Forbat, S.M., Naoumova, R.P., Sidhu, P.S., Neuwirth, C., MacMahon M., Thompson, G.R. and Underwood, S.R. (1998) The effect of cholesterol reduction with fluvastatin on aortic compliance, coronary calcification and carotid intimal-medial thickness: a pilot study. J. Cardiovasc. Risk, 5: 1-10.

183. Thompson, G.R. (1998) Serum cytokines and cardiovascular risk factors. Heart, 79: 422.

184. Riches, F.M., Watts, G.F., Naoumova, R.P., Kelly, J.M., Croft, K.D. and Thompson, G.R. (1998) Hepatic secretion of VLDL apoB in men with visceral obesity. Int. J. Obes., 22: 414-423.

185. Pfohl, M., Naoumova,R.P., Kim, K-D. and Thompson, G.R. (1998) Use of cholesterol precursors to assess changes in cholesterol synthesis under non-steady-state conditions. Eur. J. Clin. Invest., 28: 491-496.

186. Thompson, G.R. (1998) Management of hyperlipidemia. J. Saudi Heart Assoc., 10, 121-127.

187. Berger, G.M.B., Pegoraro, R.J., Patel, S.B., Naidu, P., Rom, L., Hidaka, H., Marais, A.D., Jadhav, A., Naoumova, R.P., and Thompson, G.R. (1998). HMG-CoA reductase is not the site of the primary defect in phytosterolemia. J. Lipid Res., 39, 1046-1054.

188. Riches, F.M., Watts, G.S., Naoumova, R.P., Croft, K.D. and Thompson, G.R.(1998). Hepatic secretion of very low density apolipoprotein B-100 studied with a stable isotope technique in men with visceral obesity. Int. J. Obesity, 22, 414-423.

28189. Rallides, L., Naoumova, R.P., Thompson, G.R. and Nihoyannopoulos,

P. (1998) Extent and severity of atherosclerotic involvement of the aortic root in familial hypercholesterolaemia. Heart, 80, 583-590.

190. Fruchart, J.C., Brewer, H.B., Leitersdorf, E. and Members of the Fibrate Consensus Group (1998) Consensus for the use of fibrates in the treatment of dyslipoproteinemia and coronary heart disease. Am. J. Cardiol., 81, 912-917.

191. Naoumova, R.P., Kim, K-D., Neuwirth, C., Niththyananthan, S., Rendell, N.B., Taylor, G.W. and Thompson, G.R. (1998) Cholesterol synthesis is increased in mixed hyperlipidaemia. Biochim. Biophys. Acta, 1394, 146-152.

192. Scientific Steering Committee on behalf of the Simon Broome Register Group (1999) Mortality in treated heterozygous familial hypercholesterolaemia: implications for clinical management. Atherosclerosis, 142, 105-112.

193. Naoumova, R.P., O’Neill, F.H., Dunn, S., Neuwirth, C.K.Y., Taylor, G.W., Axelson, M. and Thompson, G.R. (1999) Effect of inhibiting HMG-CoA reductase on 7-hydroxy-4-cholesten-3-one, a marker of bile acid synthesis: contrasting findings in patients with and without prior up-regulation of the latter pathway. Eur. J. Clin. Invest., 29, 408-412.

194. Thompson, G.R. (1999) Cholesterol lowering margarine is effective. BMJ, 319, 1200 (letter).

195. Thompson, G.R. (1999) The proving of the lipid hypothesis. Curr. Opin. Lipidol., 10, 201-205.

196. Thompson, G.R. and Barter, P.J. (1999) Clinical lipidology at the end of the millennium. Curr. Opin. Lipidol., 10, 521-526.

197. Thompson, G.R. and Naoumova, R.P. (2000) Novel lipid-regulating drugs. Exp. Opin. Invest. Drugs, 9, 2619-2628.

198. Thompson, G.R. and Barter, P.J. (2000) Therapeutic approaches to reducing the LDL- and HDL-associated risks of coronary heart disease. Curr. Opin. Lipidol., 11, 567-570.

199. O'Neill, F.H., Patel, D.D., Knight, B.L., Neuwirth, C.K.Y., Bourbon, M., Soutar, A.K., Taylor, G.W., Thompson, G.R. and Naoumova, R.P. (2001) Determinants of variable response to statin treatment in patients with refractory familial hypercholesterolemia. Arterioscler. Thromb. Vasc. Biol., 21, 832-837.

29200. Thompson, G.R., O'Neill, F. and Seed, M. (2002) Why some patients

respond poorly to statins and how this might be remedied. Eur Heart J., 23, 200-206.

201. Thompson, G.R. (2002) Screening relatives of patients with premature coronary heart disease. Heart, 87, 390-394.

202. Thompson, G.R., Packard, C.J. and Stone, N.J. (2002) Goals of statin therapy: three viewpoints. Current Atherosclerosis Reports, 4, 26-33.

203. Thompson, G.R. (2002) Simvastatin. Journal of Drug Evaluation: Cardiovascular Medicine, 1, 53-88.

204. Elkeles, R.S., Dunlop, A., Thompson, G.R., Neuwirth, C., Gibson, K., Rubens,

M.B. and Underwood, S.R. (2002) Coronary calcification and predicted risk of coronary heart disease in asymptomatic men with hypercholesterolaemia. J. Cardiovasc Risk , 9, 349-353.

1. Naoumova, R.P., Patel, D.D., O'Neill, F.H., Thompson, G.R. and Knight, B.L. (2003) Treatment with atorvastatin alters interleukin-12 and -10 gene expression. Eur.J. Clin. Invest.33, 88-91.

2. Thompson, G.R. (2003) LDL apheresis (review article). Atherosclerosis, 167, 1-13.

3. Chan, D.C., Watts, G.F., Barrett, P.H.R., O'Neill, F.H., Redgrave, T.G. and Thompson, G.R. (2003). Relationships between cholesterol homeostasis and triacylglycerol-rich lipoprotein remnant metabolism in the metabolic syndrome. Clinical Science, 104, 383-388.

4. Chan, D.C., Watts, G.F., Barrett, P.H.R., O'Neill, F.H. and Thompson, G.R. (2003). Plasma markers of cholesterol homeostasis and apolipoprotein B-100 kinetics in the metabolic syndrome. Obesity Research, 11, 591-596.

5. Watts, G.F., Chan, D.C., Barrett, P.H., O’Neill, F.H. and Thompson, G.R. (2003) Effect of a statin on hepatic apolipoprotein B-100 secretion and plasma campesterol levels in the metabolic syndrome. Int J Obes Relat Metab Disord, 27, 862-865.

6. Thompson, G.R., Partridge, J. (2004) Coronary calcification score: the coronary-risk impact factor. Lancet, 363, 557-59.

307. Civeira, F., International Panel on Management of Familial

Hypercholesterolemia. (2004) Guidelines for the diagnosis and management of heterozygous familial hypercholesterolemia. Atherosclerosis, 173, 55-68.

8. Naoumova, R.P., Thompson, G.R. and Soutar, A.K. (2004) Current management of severe homozygous hypercholesterolaemias. Curr Opin Lipidol, 15, 413-422.

9. Thompson, G.R. (2004) Management of dyslipidaemia. Heart, 90, 949-955.

10. O’Neill, F.H., Brynes, A., Mandeno, R., Rendell, N., Taylor, G., Seed, M. and Thompson, G.R. (2004) Comparison of the effects of dietary plant sterol and stanol esters on lipid metabolism. Nutr Metab Cardiovasc Dis, 14, 133-142.

11. Thompson, G.R. (2004) Is good cholesterol always good? BMJ, 329, 471-472.

12. Tonstad, S. and Thompson, G.R. (2004) Management of hyperlipidemia in the pediatric population. Current Treatment Options in Cardiovascular Medicine, 6, 431-437.

13. Thompson, G.R. (2004) Unpremeditated tribute to Akira Endo. Atherosclerosis Suppl 5, 29.

14. Neil, H.A.W. et al (2004) Established and emerging risk factors in patients with heterozygous familial hypercholesterolaemia. Heart, 90, 1431-1437.

15. Thompson, G.R. and Grundy, S.M. (2005) Role of plant stanol esters in cholesterol management: Introduction. Am J Cardiol, 96 (Suppl), 1-2D.

16. Thompson, G.R. and Grundy, S.M. (2005) History and development of plant sterol and stanol esterd for cholesterol-lowering purposes. Am J Cardiol, 96 (Suppl), 3-9D.

17. O’Neill, F.H., Sanders, T.A.B. and Thompson, G.R. (2005) Comparison of efficacy of plant stanol ester and sterol ester: short-term and longer-term studies. Am J Cardiol, 96 (Suppl), 29-36D.

18. Thompson, G.R. (2005) Additive effects of plant sterol and stanol esters to statin therapy. Am J Cardiol, 96 (Suppl), 37-39D.

3119. Humphries, S.E. et al (2006) Genetic causes of familial

hypercholesterolaemia in UK patients: relation to plasma lipid levels and coronary heart disease risk. J Med Genet, 43, 943-949.

20. Ellis, S.M., Naoumova R.P., Neuwirth C.K., Eckersley R., Cosgrove D.O., Thompson G.R., Sidhu P.S. (2007) Measurement of the reflectivity of the intima-medial layer of the common carotid artery improves the discriminatory value of intima-medial thickness measurement as a predictor of risk of atherosclerotic disease. Ultrasound in Med & Biol. 33, 1029-38.

225. Thompson G.R. (2008) HEART-UK LDL Apheresis Working Group. Recommendations for the use of LDL apheresis. Atherosclerosis 198, 247-255.

226. Sarwar R, Neuwirth C, Walji S, Tann Y, Seed M, Thompson GR, Naoumova RP. (2008) Efficacy of ezetimibe and future role in the management of refractory hyperlipidaemia in high-risk patients. Br J Cardiol 15, 205-209.

227. Thompson, G.R. (2009) History of the cholesterol controversy in Britain. Q J Med, 102, 81-6.

228. Thompson G. (2009) History of the cholesterol hypothesis in Britain. Q J Med, 102,

750-1.

229. Maher V.M., Kitano Y., Neuwirth C., Davies G.J., Maseri A., Thompson G.R., Andreotti F. (2009) Plasminogen activator inhibitor-1 removal using dextran sulphate columns. Evidence of PAI-1 homeostasis. J Thromb Thrombolysis, 28, 166-172.

230. Thompson G.R., Barbir M., Davies D., Dobral P., Gesinde M., Livingston M., Mandry P., Marais A.D., Matthews S., Neuwirth C., Pottle A., le Roux C., Scullard D., Tyler C., Watkins S. (2010) Efficacy criteria and cholesterol targets for LDL apheresis. Atherosclerosis, 208, 317-21.

231. Thompson G. (2010) Which lipid fraction is the target and how often should this be monitored? Heart, 96, 413-4.

232. Thompson G.R. (2010) Lipoprotein apheresis. Curr Opin Lipidol, 21, 487-91.

233. Thompson G.R., Catapano A., Saheb S., Atassi-Dumont M., Barbir M., Eriksson M., Paulweber B., Sijbrands E., Stalenhoef A., Parhofer K.G. (2010) Severe hypercholesterolaemia:

32therapeutic goals and elegibility criteria for LDL apheresis in Europe. Curr Opin Lipidol, 21, 492-98.

234. Thompson G.R. (2011). Role of plant sterols in lipid lowering – a safety issue. Q J Med, 104, 729-31.

235. Thompson G.R. (2012) Cardiovascular disease prevention and the rise in dementia. Q J Med, 105, 93-7.

236. Seed M., Betteridge J., Cooper J., Caslake M., Durrington P.N., Thompson G.R., Sattar N., Humphries S.E. and Neil H.A.W. (2012). Normal levels of inflammatory markers in treated patients with fasmilial hypercholesterolaemia: a cross-sectional study. J R Soc Med Cardiovasc Dis, 1, 1- 9.

237. Thompson G.R. (2013). The evidence- base for the efficacy of lipoprotein apheresis in combating cardiovascular disease. Atherosclerosis Supplements,14, 67-70.

238. Walji S., Neuwirth C. and Thompson G.R. (2013). Lipoprotein apheresis for the treatment of familial hypercholesterolaemia. Clinical Lipidology, 8, 573-586.

239. Thompson G.R. and Seed M. (2014). Lipoprotein (a): the underestimated cardiovascular risk factor. Heart, 100, 534-535.

240. Stefanutti C. and Thompson G.R. (2014) Lipoprotein apheresis in the management of familial hypercholesterolaemia: historical perspective and recent advances. Curr Athero Rep, 17, 465-474.

241. Thompson G. R. (2015) Managing homozygous familial

hypercholesterolaemia from cradle to grave. Atherosclerosis Suppl. 18, 16-20.

242. Carter N. J., Hill N.E., Nicol E.D., Hollis S., Patil Mead M.L. and

Thompson G. R. (2015) Dyslipidaemia and the military patient. J R Army Med Corps, 161, 206-210.

243. Thompson G.R., Seed M., Naoumova R., Neuwirth C., Walji S., Aitman T.J., Scott J., Myant N.B. and Soutar A.K. (2015) Improved cardiovascular outcomes following temporal advances in lipid-lowering therapy in a genetically characterised cohort of familial hypercholesterolaemia homozygotes. Atherosclerosis, 243, 328-333.

244. Thompson, G.R. (2015) Obituary of Dr N.B. Myant. Atherosclerosis, 240, 437-8.

33 245. Gibbons G., Soutar A. K., Thompson, G. (2015) In Memoriam: Nick Myant (1917- 2015) Journal of Lipid Research, 56, 1081-4.

246. Thompson, G.R. (2016) The Nobel dilemma: to reward scientific discovery or benefit to mankind? QJM : An International Journal of Medicine, 109, 513-4.

247. France M., Rees A., Datta D., Thompson G., Capps N., Ferns G., Ramaswami U., Seed M., Neely D., Cramb R., Shoulders C., Barbir M., Pottle A., Eatough R., Martin S., Bayly G., Simpson B., Halcox J., Edwards R., Main L., Payne J., Soran H., for HEART UK Medical Scientific and Research Committee (2016) HEART UK statement on the management of homozygous familial hypercholesterolaemia in the United Kingdom. Atherosclerosis, 255, 128-139.

248. Thompson G. (2017) Limitations of cholesterol lowering with PCSK9 inhibitors. Lancet Diab Endocrinol , 5, 241-3.

249. Thompson G.R., Blom D.J., Marais A.D., Seed M., Pilcher G.J., and Raal F.J. (2017) Survival in homozygous familial hypercholesterolaemia is determined by the on-treatment level of serum cholesterol. Eur Heart J doi:10.1093/eurheartj/ehx317.

Conference contributions and other works

1. Thompson, G.R., Neale, G., Lewis, B., Watts, M. and Booth, C.C. (1967) Plasma vitamin D-like activity and vitamin D absorption in man. In: L’Ostéomalacie (ed. D.J. Hioco), pp. 337-341. Masson & Co, Paris.

2. Joplin, G.F., Robinson, C.J., Melvin, K.E.W., Thompson, G.R. and Fraser, R. (1967) Results in tracer studies in osteomalacia. In: L’Ostéomalacie (ed. D.J. Hioco), pp. 249-256. Masson & Co, Paris.

3. Thompson, G.R. (l968) Studies in the absorption and metabolism of vitamin D3 after gastric surgery. Postgrad. Med. J., 44, 626-628.

4. Thompson, G.R. (1969) Studies in the absorption and metabolism of vitamin D. In: Bibliotheca Nutritio et Dieta (ed. J.C. Somogyi), pp. 58-59. S. Karger, Basel/New York.

5. Thompson, G.R. (l97l) Absorption of fat-soluble vitamins and sterols. J. Clin. Path., 24 (Suppl. 5 (Roy. Coll. Path.), 85-89.

346. Soutar, A.K., Myant, N.B. and Thompson, G.R. (l978) Simultaneous

measurement of VLDL-apoB and LDL-apoB synthesis in familial hypercholesterolaemia. In: Protides of the Biological Fluids (ed. H. Peeters), pp. l75-l78. Pergamon Press, Oxford.

7. Thompson, G.R. (l978) Familial hypercholesterolaemia. In: NATO Advanced Study Institute Series A, Life Sciences, Vol.l5. The Lipoprotein Molecule (ed. H. Peeters), pp. 2l5-226. Plenum Press, New York.

8. Thompson, G.R. (l978) Causes and consequences of hypocatabolism of LDL. In: International Conference on Atherosclerosis (ed. L.A. Carlson, R. Paoletti and G. Weber), pp. 279-282. Raven Press, New York.

9. Thompson, G.R. (l978) Clinical applications of plasma exchange. IBM Medical Review, December, pp. l3-16.

10. Thompson, G.R. (l978) Therapeutic use of plasma exchange in familial hypercholesterolaemia. In: Diabetes, Obesity and Hyperlipidemias (eds. G. Crepaldi, P.J. Lefebvre and K.G.M.M. Alberti), pp. 35l-354. Academic Press, London.

11. Thompson, G. (l979) Human oil change. World Medicine, l4, 6l-62.

12. Thompson, G. (l980) Effect of diet on the incidence of coronary disease. Postgrad. Doctor - Middle East, January, 28-33.

13. Thompson, G.R. (l980) Uptake and cellular degradation of low density lipoproteins. Nutr. Metabolism Suppl., 24, Suppl. l, l2-18.

14. Thompson, G., Myant, N., Oakley, C., Steiner, R. and Sapsford, R. (l980) Commbined medico-surgical strategy for severe familial hypercholesterolaemia. In: Atherosclerosis V, Proceedings of the 5th International Symposium on Atherosclerosis (eds. A.M. Gotto, L.C. Smith and B. Allen), pp. 454-457. Springer-Verlag, New York.

15. Thompson, G.R. (l980) Plasma exchange for hypercholesterolaemia: a therapeutic mode and investigative tool. Plasma Therapy, l, 5-l5.

16. Thompson, G.R. (l980) The lipid hypothesis. Acta med. Scand., 208, 34l-342.

17. Thompson, G.R. (l98l) Pathology of endocytosis with special reference to lipoproteins. In: Proceedings of the Boerhaave Course 'Cell Biological Aspects of Disease: The plasma membrane and lysosomes' (eds. W.T. Daems, B.A. Afzelius and E.H. Burger), pp. 20l-209. Martinus Nijhoff Publishers, The Hague.

35

18. Thompson, G.R. (l98l) Catabolism of low density lipoprotein. In: Metabolic Risk Factors and Ischemic Cardiovascular Disease (eds. B. Pernow and L.A. Carlson), pp. 73-84. Raven Press, New York.

19. Thompson, G.R. (l98l) Long-term plasma exchange in severe familial hypercholesterolemia. In: Proceedings of the Workshop on Therapeutic Plasmapheresis and Cytapheresis (eds. G.J. Nemo and H. Taswell), pp. 235-246. NIH Publication No. 82-l665.

20. Thompson, G.R. (l98l) Plasma exchange in hyperlipidemia. In: Therapeutic Plasma Exchange (eds. H.J. Gurland, V. Heinze and H.A. Lee), pp. 89-96. Springer-Verlag, Berlin, Heidelberg, New York.

21. Thompson, G.R. (l98l) Making sense of hyperlipidaemia in general practice. Mod. Med., Cardiology, Postgraduate Partwork Series Part l, 3-ll.

22. Spengel, F.A., Harders-Spengel, K.M., and Thompson, G.R. (1982) Diätetische und medikamentöse Therapie von Hyperlipidämien. Ernährungs-Umschau, 29, 100-103.

23. Thompson, G. (l982) Lipids, lipoproteins and hyperlipidaemias. MIMS Mag., October, 7-ll.

24. Myant, N.B. and Thompson, G.R. (l982) Receptor-deficient hyper-lipidaemia. In: Advances in Pathology, Vol. I (ed. E. Levy), pp. l37-l53. Pergamon Press, Oxford and New York.

25. Thompson, G.R. (l983) Interrelationship between plasma phospho-lipids and low density lipoprotein turnover. In: Phospholipids and Atherosclerosis (eds. P. Avogaro, M. Mancini, R. Paoletti and G. Ricci), pp. l43-l58. Raven Press, New York.

26. Thompson, G.R. and Spengel, F.A. (l983) Defects of receptor-mediated low density lipoprotein catabolism. In: Diabetes, Obesity and Hyperlipidemias II (eds. G. Crepaldi, P.J. Lefebvre and D.J. Galton), pp. 53-58. Academic Press, London.

27. Thompson, G.R. (l983) Radical therapy of hypercholesterolaemia and atherosclerosis. In: Arterial Pollution. An integrated view on Atherosclerosis (eds. H. Peeters, G.A. Gresham and R. Paoletti), NATO Advanced Study Institute Series, Series A: Life Sciences, 58, 37l-389. Plenum Press, New York.

28. Thompson, G.R. (l983) Plasma exchange and affinity chromatographic therapy for hyperlipidaemia: a review. Apheresis Bull., l, 26-3l.

36

29. Thompson, G.R. (l983) Low density lipoprotein. In: Conference on Arterial Wall Metabolism (eds. M.R. Malinow, B.G. Brown, R.W. Wissler, O. Stein, Y. Stein, S.M. Schwartz, G. Schonfeld, E.J. Schaefer and G.R. Thompson). Arteriosclerosis, 3, 629-630.

30. Thompson, G.R. (l983) Factors influencing receptor-mediated low density lipoprotein catabolism. In: Atherosclerosis VI, Proceedings of the 6th International Symposium on Atherosclerosis, pp. 559-563.

31. Thompson, G.R., Myant, N.B. and Soutar, A.K. (l984) Turnover of VLDL-and IDL-apoB in controls and patients with familial hypercholesterolaemia. In: Latent Dyslipoproteinemias and Atherosclerosis (eds. J.L. de Gennes et al), pp. 87-92. Raven Press, New York.

32. Thompson, G. (l984) Fat absorption and metabolism. Gastroenterol. Jap., l9, 25l-259.

33. Thompson, G.R. (l984) Role of plasma apolipoproteins. In: Hammersmith Cardiology Workshop Series, vol. 1 (eds. A. Maseri and J. Goodwin), pp. 89-92. Raven Press, New York.

34. Thompson, G.R., Teng, B. and Sniderman, A.D. (l984) Turnover of apoB in low density lipoprotein sub-fractions. In: AAS l6 Cologne Atherosclerosis Conference. No. 2: Lipids (ed. M.J. Parnham), pp. l2l-l25. Birkhauser Verlag, Basel.

35. Thompson, G.R. (l984) Receptor-deficient hyperlipidaemia. In: Atherosclerosis and Cardiovascular Disease. Etiopathogenesis, epidemiology, clinical evaluation, prevention and therapy (eds. S. Lenzi and G.C. Descovich), pp. 29-35. MTP Press Ltd., Lancaster.

36. Postiglione, A. and Thompson, G.R. (l985) Experience with plasma exchange in homozygous familial hypercholesterolaemia. In: Detection and treatment of lipid and lipoprotein disorders of childhood. Progress in Clinical and Biological Research, vol. l88 (eds. K. Widhalm and H.K. Naito), pp. 2l3-230. Alan R. Liss Inc., New York.

37. Thompson, G.R., Teng, B. and Sniderman, A.D. (l985) Effects of stimulating receptor-mediated LDL catabolism on turnover of LDL sub-fractions in familial hypercholesterolemia. In: Recent Advances in Bile Acid Research, (eds. L. Barbara, R. Hermon Dowling, A.F. Hofmann, and E. Roda), pp. l99-205. Raven Press, New York.

3738. Thompson, G.R., Teng, B. and Sniderman, A.D. (l985) Contrasting

features of overproduction versus decreased removal of apoB. In: Diabetes, Obesity and Hyperlipidemias - III (eds. G. Crepaldi, A. Tiengo and G. Baggio), pp. 59-63. Excerpta Medica, Elsevier Science Publishers BV.

39. Thompson, G.R. (l985) The role of lipoproteins in the transport of fats in plasma. In: The role of fats in Human Nutrition (eds. F.B. Padley and J. Podmore in collaboration with J.P. Brun, R. Burt and B.W. Nicols), pp. l46-l56. VCH, Weinheim, F.R. Germany and Ellis Horwood Ltd., Chichester, England.

40. Thompson, G.R. (l985) Detection and management of hyperlipo-proteinaemia in the aftermath of the Lipid Research Clinics Trial. Current Medical Literature: Cardiovascular Medicine, 4, l27-l29.

41. Thompson, G.R. (l986) Radical therapy for familial hyper-cholesterolaemia. In: Lipoproteins and Coronary Heart Disease (eds. J. Shepherd et al)., pp. l53-l57. Proceedings of the Glasgow Heart Disease Symposium l984.

42. Thompson, G.R. (l986) Should we lower lipid levels? MIMS Mag, Jan. lst, 45-52.

43. Thompson, G.R. (l986) Lowering blood lipids. Mims Mag, l5th Feb., l9-23.

44. Thompson, G.R. (l986) Is atheroma reversible? Cardiology in Practice, 4, l8-20.

45. Thompson, G.R. (l986) Can we regress atheromatous lesions in humans? In: Perspectives in Lipid Disorders, 3, 4-9. Postgraduate Medicine: Custom Communications, Parke-Davis, New Jersey.

46. Thompson, G.R., Trayner, I.A.M., Allaway, S.L., Robinson, D. and Ritchie, C.D. (l986) Hyperapobetalipoproteinaemia: an emerging risk factor for atherosclerosis. In: Monographs on Atherosclerosis (eds. A. Ventura, G. Crepaldi and U. Senin). Monogr. Atheroscler., l4, l29-l3l. Karger, Basel.

47. Kano, M., Jadhav, A., Koizumi, J. and Thompson, G.R. (l986) Turnover of light and heavy fractions of human LDL in normal and WHHL rabbits. In: Receptor-mediated uptake in the liver (eds. H. Greten, E. Windler and U. Beisiegel), pp. 66-68. Springer-Verlag, Berlin.

3848. Thompson, G.R. (l986) Familial hypercholesterolaemia: overcoming

the metabolic defect. In: Atherosclerosis VII (eds. N.H. Fidge and P.J. Nestel), pp. l77-l80. Elsevier Science Publishers B.V. (Biomedical Division), Amsterdam.

49. Thompson, G.R. (l986) Pathogenesis of atherosclerosis. Pharmacy International, 7, 276-279.

50. Thompson, G.R. and Jadhav, A. (l986) Control of plasma HDL levels after plasmapheresis. In: Lipoprotein deficiency syndromes (eds. A. Angel and J. Frohlich), Advances in Experimental Medicine and Biology, 20l, l27-l35. Plenum Press, New York.

51. Thompson, G.R., Robinson, D., Allaway, S.L., Bevan, E.A. and Ritchie, C.D. (l987) Prevalence of hyperlipidaemia in British compared with North American men. In: Expanding horizons in atherosclerosis research (eds. G. Schlierf and H. Morl), pp. ll4-l2l. Springer Verlag, Berlin.

52. Thompson, G.R., Kano, M. and Reeve, J. (l987) Turnover and interconversion of LDL sub-fractions. In: Lipoproteins and atherosclerosis (eds. C.L. Malmendier and P. Alaupovic). Advances in Experimental Medicine, 2l0, l05-l09. Plenum Press, New York.

53. Thompson, G.R. (l987) Has the evidence now brought cholesterol debate to a close? Pulse, 47, 84.

54. Thompson, G.R. (l987) Genetic and environmental determinants of plasma lipoproteins relevant to coronary heart disease. Br. J. Clin. Pract., 4l (Suppl. 54), 47-5l.

55. Koizumi, J., Postiglione, A., Knight, B.L., Soutar, A.K. and Thompson, G.R. (l987) Effects of polyunsaturated phospholipid on cholesterol efflux in vitro and in experimental animals and human subjects. In: Drugs affecting lipid metabolism (eds. Paoletti, R., Kritchevsky, D. and Holmes, W.L.), pp. 403-406. Springer Verlag, Berlin, New York.

56. Thompson, G.R. (l987) Management of hyperlipidaemia. Drugs and Therapeutic Bulletin, 25, 89-92 [written anonymously].

57. Thompson, G.R. and Okabayashi, K. (l988) Plasma exchange and LDL apheresis. In: Recent aspects of diagnosis and treatment of lipoprotein disorders: impact on prevention of atherosclerotic diseases (ed. K. Widhalm and H.K. Naito), pp. 3ll-3l6. Alan R. Liss Inc., New York.

58. Thompson, G.R. (l988) Lipid-lowering therapy in perspective. Br. J. Clin. Pract., 42, 6l-64.

39

59. Thompson, G.R. (l988) Detection and management of hyper-lipidaemia. Mod. Med., 33, 380.

60. Thompson, G.R. (l988) Criteria for treating the patient with hyperlipidaemia. Mod. Med., 33, 379.

61. Thompson, G.R. (l988) Hyperlipidaemia: causes, classification and clinical features. Irish Med. Times, June l7, l8-l9.

62. Thompson, G.R., Kano, M. and Koizumi, J. (l988) Therapeutic mobilization of tissue cholesterol. In: Hyperlipidaemia and atherosclerosis (eds. K.E. Suckling and P.H.E. Groot), pp. 83-l02. Academic Press, London.

63. Thompson, G.R. (l988) Extracorporeal cholesterol removal. Internat. Lipid Forum, 1, 1-6.

64. Thompson, G.R. (l988) Clinical consequences of hyperlipidaemia. J. Inher. Metab. Dis., 11 (Suppl. l), l8-28.

65. Thompson, G.R. (l988) Normal and pathological lipoprotein metabolism. Drugs, 36 Suppl 3, 5l-54.

66. Thompson, G.R. (l989) Cholesterol-lowering agents. In: Horizons in Medicine (ed. C. Bunch), pp. l-ll. Baillière Tindall, London.

67. Thompson, G.R. (l989) Lipid-lowering therapy and its effect on atherosclerosis. Postgrad. Med. J., 65 Suppl l, S22-S25.

68. Thompson, G.R. (l989) LDL subfractions and atherosclerosis. In: Lipoprotein Subfractions Omega-3 Fatty Acids (ed. H.U. Klör), pp. 62-67. Springer-Verlag, Berlin, Heidelberg.

69. Thompson, G.R. (l989) Lipid related consequences of intestinal malabsorption. Gut Festschrift, pp. 29-34.

70. Thompson, G.R. (l989) Atherosclerotic arteries and cholesterol. MRC News, no. 45, 26-27.

71. Thompson, G.R., Barbir, M., Michishita, I. and Larkin, S. (l989) Comparison of plasma exchange and LDL apheresis in the treatment of hypercholesterolaemia. In: Atherosclerosis VIII (eds G. Crepaldi et al), pp. 8l5-8l8. Elsevier Science Publishers BV, Amsterdam.

72. Thompson, G.R. (l990) The importance of hyperlipidaemia. Cardiology in Practice, 8, 28-32.

4073. Thompson, G.R. (1990) History and evolution of extracorporeal LDL

elimination in severe hypercholesterolaemia. In: Treatment of severe hypercholesterolemia in the prevention of coronary heart disease - 2 (eds Gotto AM Jr, Mancini M, Richter WO, Schwandt P). pp. 164-169. Proc. 2nd Int. Symp Munich 1989, Karger.

74. Thompson, G.R. (l990) Oestrogen and raised blood lipids. Mims Mag., 15 Jan, 22.

75. Thompson, G.R. (l990) Towards a new era: is coronary artery disease reversible? Cardiology, 77, suppl. 4, 66-69.

76. Thompson, G.R. (l990) Mobilisation of tissue cholesterol by apheresis. In: Apheresis (ed. G. Rock), pp. 183-187. Alan R. Liss Inc., New York.

77. Thompson, G.R., Koizumi, J. and Michishita, I. (l990) Cholesterol-mobilizing capability of apolipoprotein A-I/phosphatidylcholine complexes. In: Disorders of HDL. Proceedings of the International Symposium, Karolinska Hospital, Stockholm, 7-8 June 1990 (ed. L.A. Carlson), pp. 225-232. Smith-Gordon., London.

78. Thompson, G.R. and Michishita, I. (l990) Therapeutic reduction of cholesterol accumulation. In: Drugs affecting lipid metabolism X (eds. A.M. Gotto and L.C. Smith), pp. 377-380. Elsevier, Amsterdam.

79. Koizumi, J. and Thompson, G.R. (1990). Effects of infusing apoHDL/phosphatidylcholine complexes into normal and hyper-cholesterolemic rabbits. In: 50th Anniversary of Phospholipid Research (EPL) (eds. Gundermann, K-J and Schumacher, R.), pp. 149-158. wbn Verlag, Bingen/Rhein.

80. Maher V.M.G. and Thompson, G.R. (l990) Analysis of evidence from cholesterol-lowering and regression trials. J. Drug Dev., 3, Suppl. 1, 199-203.

81. Thompson, G.R. (1991) Towards a new era - prospects for regression in hypercholesterolaemia. In: HMG-CoA reductase inhibitors: New horizons in the management of hyperlipidaemia (eds P.J. Nestel and A. Yamamoto), pp. 32-35. Excerpta Medica Pty Ltd., Australia.

82. Thompson, G.R. (1991) Oestrogen and raised blood levels. Mims Mag., 15 Jan, p.22.

83. Thompson, G.R. (1991) L'approccio al paziente nalla Lipid Clinic dell'Hammersmith Hospital di Londra. Cholesterol News, III, no. 4, 7-8.

4184. Thompson, G.R. (1991) Therapeutic implications of raised levels of

lipoprotein(a). In: Lipoproteins and the pathogenesis of atherosclerosis (eds. J. Shepherd, C.J. Packard, and S.M. Brownlie), pp. 91-96. Elsevier Science Publishers, Amsterdam.

85. Kitano, Y., Neuwirth, C., Maher, V. and Thompson, G.R. (1992) LDL apheresis - State of the art. In: Treatment of severe dyslipoproteinemia in the prevention of coronary heart disease 3 (ed W.O. Richter), pp. 319-326. Karger, Munchen.

86. Thompson, G.R. (1992) Historical perspective and rationale of use of low-density lipoprotein apheresis to treat familial hypercholesterol-emia. In: The treatment of severe hypercholesterolemia: can we impact disease course? (eds. B.R. Gordon and A.M. Gotto Jr.), pp. 57-62. Excerpta Medica Inc., Princeton.

87. Thompson, G.R. (1993) Regression of coronary artery disease. In: Cardiovascular Disease. Risk Factors and Intervention (eds. N. Poulter, P. Sever and S. Thom), pp. 325-329. Radcliffe Medical Press, Oxford.

88. Thompson, G.R. (1993) Lipids and the cardiovascular system. Med. Internat., 21, 373-376.

89. Thompson, G.R. (1993) When should patients with hyperlipidaemia be referred? Pulse, March 27th, 73-76.

90. Kitano, Y. and Thompson, G.R. (1993) Randomized trial of low density lipoprotein apheresis to treat coronary artery disease in familial hypercholesterolaemia. In: Therapeutic Plasmapheresis (XII) (eds. T. Agishi et al), pp. 25-28. VSP, The Netherlands.

91. Thompson, G.R. (1993) Regression of atherosclerosis - what is the evidence? Risk, 1, 11-14.

92. Thompson, G.R. (1993) Degrees of risk. In: Issues in Hyperlipidaemia. No. 7. Sanofi Winthrop Ltd., Kluwer Academic Publishers, Lancaster.

93. Thompson, G.R. (1993) Clinical identification of high risk hyperlipidaemia. In: Cholesterol Lowering Trials (eds .M.F. Laker, A. Neil and C. Wood), pp. 33-44. Royal College of Physicians of London on behalf of The British Hyperlipidaemia Association.

94. Thompson, G.R. (1994) Addisonian Hyperlipidaemias. In: Advances in Thomas Addison's Diseases, vol. 1. (eds. M. Besser, R. Bhatt, F. Bottazzo, F. Fallo, V.H.T. James, and H. Keen), pp. 21-28. Journal of Endocrinology Ltd., Bristol.

42

95. Thompson, G.R. and Sussekov, A. (1995) Radical therapy of atherosclerosis by apheresis or liver transplantation. In: Atherosclerosis X (eds Woodford, F.P., Davignon, J. and Sniderman, A.), pp. 549-552. Elsevier Science BV, The Netherlands.

96. Thompson, G.R. (1995) Non-invasive detection and targeted treatment of asymptomatic atherosclerosis in high-risk individuals. Lipid Review, 9, 6-9.

97. Thompson, G.R. (1995) Therapeutic role of apheresis. CardioGuardian, 1: 7-10.

98. Thompson, G.R. (1996) LDL apheresis and liver transplantation in the management of familial hypercholesterolaemia in childhood. In: Hyperlipidaemia in Childhood. (A. Neil, A. Rees and C. Taylor, eds). Royal College of Physicians Publications, London, pp. 67-75.

99. Thompson, G.R. (1996) Statins - for whom should they be prescribed? Postgrad. Doctor Middle East, 19: 310-313.

100. Thompson, G.R. (1996) HMG-CoA reductase inhibitor therapy: Percent reduction in LDL cholesterol or target level on treatment? Cardiology in Review, 1: 5-8.

101. Marais, A.D., Firth, J.C., Naoumova, R.P. and Thompson, G.R. (1996) The role of HMG CoA reductase inhibitors in homozygous familial hypercholesterolemia. In: Drugs affecting lipid metabolism (A.M. Gotto Jr. et al (eds)). The Netherlands: Kluwer Academic Publishers and Fondazione Giovanni Lorenzini, pp. 181-186.

102. Thompson, G.R. and Kitano, Y. (1997) The role of low density lipoprotein apheresis in the treatment of familial hypercholesterolemia. Therapeutic apheresis 1: 13-16.

103. Thompson, G.R. (1997) Case study: Nyamugunduru, G. and Roper, H. Childhood onset insulin dependent diabetes presenting with severe hyperlipidaemia. Brit. Med.J., 314: 62-65.

104. Thompson, G.R. (anonymous) (1997) Hazards of running a marathon. Grand Rounds – Hammersmith Hospital. Br. Med. J. 314: 1023-1025.

105. Kitano, Y. and Thompson, G.R. (1997) The Familial Hypercholesterolaemia Regression Study: a randomized comparison of therapeutic reduction of both low-density lipoprotein and lipoprotein(a) versus low-density lipoprotein alone. Therapeutic Apheresis, 1: 187-190.

43

106. Thompson, G.R. (1998) The clinical case for triglyceride-rich lipoproteins. In: Atherosclerosis XI (B. Jacotot, D. Mathe and J.C. Fruchart, eds). Elsevier Science (Singapore) Pte Ltd., 599-603.

107. Thompson, G.R. (1998) Foreword: Coronary risk factors beyond LDL: triglyceride-rich lipoproteins. Proceedings of a meeting held in Madeira, 19.4.97. Eur. Heart J., 19, H1.

108. Thompson, G.R. (1998) Angiographic evidence for the role of triglyceride-rich lipoproteins in progression of coronary artery disease. Eur. Heart J., 19, H31-H36.

109. Thompson, G.R. (1998) Pathogenesis and prevention of atherosclerosis in aortocoronary saphenous bypass grafts. Issues in Prevention Cardiology, vol. 1.2, 8-12.

110. Thompson, G.R. (1998) Introduction. A symposium: Cerivastatin: clinical efficacy and safety in the management of hyperlipidemia. Am. J. Cardiol., 82, 1J-2J.

111. Thompson, G.R. and Grundy, S.M. (1999) Foreword: New approaches to dietary management of elevated cholesterol. Eur. Heart J. Suppl.,1, S1-S2

112. Thompson, G.R.(1999) Poor responders to statins: a potential target for stanol esters. Eur. Heart J. Suppl., 1, S114-S117.

113. Thompson, G.R. (1999) Plant lipids that lower serum cholesterol. Eur. Heart J., 20, 1527-1529.

114. Thompson, G.R. (1999) Target levels for lipid-lowering therapy in the prevention of CHD: the lower the LDL the better? CardioGuardian, 2, 3-6.

115. Thompson, G.R. (2001) Genetic influence on cholesterol absorption and its therapeutic consequences. In: Dietary cholesterol as a cardiac risk factor: myth or reality? (A.R. Leeds and J. Gray, eds) pp.27-33. Smith-Gordon, London.

116. Thompson, G.R. (2002) Significance of cholesterol absorption: inhibitory role of plant sterols and stanols. In: Nutrition and Health. (T. Carr and K. Descheemaeker, eds) pp. 27-33. Blackwell Science, Oxford.

44117. Thompson, G. (2002) Current and future trends in lipid-regulating

therapy. In: The Year in Dyslipidaemia 2002. ( P. Durrington, M. Mackness, P. Miller and A. Rees, eds) pp 335-344. Clinical Publishing Services, Oxford.

118. Thompson, G.R. (2002) Prescribing statins: the goalposts have moved. Postgraduate Doctor Caribbean, 18, 99-104.

119. Thompson, G.R. (2004) New developments in pharmacotherapy. Cardiovasc J S Afr, 15, 56-58.

120. Tonstad, S. and Thompson, G.R. (2004) Management of hyperlipidemia in the pediatric population. Curr Treat Options Cardiovasc Med, 6, 431-437.

121. Thompson, G.R. (2004) Use of plasma markers as indices of sterol metabolism. In: Atherosclerosis X111 (Y. Matzuzawa, T. Kita, R. Nagai and T. Teramoto, eds). International Congress Series 1262, 603-606.

122. Thompson, G.R. (2004) Fishing and longevity. Atheroma, 8, 4-5.

123. Thompson, G.R. (2007) A case of xanthomatous neuropathy. In: Case studies in lipid management (D.J. Betteridge, ed), Informa Healthcare.

125. Thompson, G.R. (2008) Lasker Award for the discoverer of statins. Br J Cardiol, 15, 294-5.

126. Thompson, G.R. (2010) Clinical Lipidology. Incitament, 19, 503-7.

127. Thompson, G.R. (2014) Meeting unmet needs in homozygous familial hypercholesterolaemia. Cardiology News, 17, 10-13.

128. Thompson G.R. and Seed M. (2014) The management of familial hypercholesterolaemia. Primary Care Cardiovascular Journal doi:10.3132/pccj.2014.014.